Oxycodone is metabolized primarily in the liver through two enzymatic pathways. The major route removes a methyl group to produce noroxycodone, a mostly inactive byproduct. The minor route produces oxymorphone, a metabolite that is significantly more potent at opioid receptors. About 10% of the drug passes through unchanged and is excreted in urine. Understanding these pathways matters because genetics, other medications, and organ function can all shift how your body processes the drug, changing both its effectiveness and its risk of side effects.
The Two Main Liver Pathways
The liver handles oxycodone through two enzyme families. The dominant pathway uses CYP3A4 enzymes to convert oxycodone into noroxycodone through a process called N-demethylation. This is the quantitatively larger route, meaning most of the drug flows through it. Noroxycodone has weak pain-relieving properties and does not contribute much to the drug’s clinical effect.
The second pathway uses CYP2D6 enzymes to convert oxycodone into oxymorphone through O-demethylation. Although this pathway handles a smaller share of the drug, it produces the metabolite that matters most for pain relief. Oxymorphone binds to the same opioid receptors as oxycodone and is active in the brain. Both metabolites can undergo further breakdown into noroxymorphone, which does bind opioid receptors but crosses into the brain poorly, limiting its effect.
What Happens After Metabolism
Once broken down, oxycodone and its metabolites are cleared through the kidneys. Roughly 23% of a dose appears in urine as free noroxycodone, about 10% as conjugated oxymorphone, and around 9% as free and conjugated oxycodone. Less than 1% shows up as free oxymorphone. The remainder undergoes additional chemical modifications in the liver, including glucuronidation (a process that tags molecules for easier kidney excretion) and reduction reactions.
How Fast Oxycodone Moves Through Your System
For immediate-release formulations, oxycodone reaches peak blood levels in about 1.6 hours and has an elimination half-life of roughly 3.2 hours. That means half the drug is cleared from your blood every three hours or so, and the drug is largely gone within 16 to 19 hours. Extended-release formulations peak later, around 2.7 to 3.2 hours, and have a longer apparent half-life of about 4.5 hours because the tablet releases the drug gradually.
Why Genetics Change How You Respond
The CYP2D6 enzyme that produces oxymorphone varies dramatically from person to person based on genetics. People fall into four broad categories: poor metabolizers with non-functioning CYP2D6, intermediate metabolizers with low-functioning CYP2D6, normal metabolizers, and ultra-rapid metabolizers who carry extra gene copies.
These differences have real consequences. In poor metabolizers, the ratio of oxycodone to oxymorphone in plasma is roughly 300 to 1, meaning almost no active oxymorphone is produced. In normal metabolizers, that ratio drops to about 43 to 1. In ultra-rapid metabolizers, it falls to around 32 to 1, with oxymorphone contributing nearly equally to opioid receptor activation in the brain. Poor metabolizers may get less pain relief from standard doses, while ultra-rapid metabolizers face a higher risk of exaggerated effects because more of the drug is converted to the potent oxymorphone form.
Drug Interactions That Shift Metabolism
Because CYP3A4 handles the bulk of oxycodone metabolism, anything that slows this enzyme down will raise oxycodone levels in the blood. Common CYP3A4 inhibitors include certain antibiotics like erythromycin and ciprofloxacin, antifungal medications like ketoconazole and itraconazole, and some HIV medications. This increase in drug exposure can cause dangerous respiratory depression, particularly if an inhibitor is added after someone has been on a stable oxycodone dose.
The combination of a CYP2D6 inhibitor (such as paroxetine, an antidepressant) and a CYP3A4 inhibitor at the same time greatly increases oxycodone exposure because both exit routes are partially blocked.
Going the other direction, CYP3A4 inducers speed up the enzyme and reduce oxycodone levels, potentially making pain control inadequate. Dexamethasone, a corticosteroid frequently used alongside opioids in cancer care, is one of the most common inducers encountered in practice. Other inducers include the seizure medications carbamazepine and phenytoin, and the antibiotic rifampin. Stopping one of these inducers while still taking oxycodone can cause a rebound spike in drug levels as the enzyme slows back down.
Liver and Kidney Impairment
Since the liver does nearly all the metabolic work, impaired liver function leads to significantly higher oxycodone concentrations in the blood. The FDA label recommends starting at one-third to one-half the usual dose in people with hepatic impairment.
Kidney disease affects the elimination side of the equation. In people with reduced kidney function (creatinine clearance below 60 mL/min), oxycodone plasma concentrations run approximately 50% higher than normal. The metabolites noroxycodone and oxymorphone can also accumulate because the kidneys can’t clear them efficiently. Older adults are especially vulnerable here because kidney function naturally declines with age, and the combination of slower clearance with age-related sensitivity to opioids compounds the risk. For older adults with chronic kidney disease, recommended starting doses are typically 2.5 to 5 mg every four to six hours, with careful monitoring.